New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …
[HTML][HTML] Rationalizing antimicrobial therapy in the ICU: a narrative review
The massive consumption of antibiotics in the ICU is responsible for substantial ecological
side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this …
side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
[HTML][HTML] Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …
Managing Acinetobacter baumannii infections
J Garnacho-Montero, JF Timsit - Current opinion in infectious …, 2019 - journals.lww.com
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …
[HTML][HTML] Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity
Polymyxins are valuable antimicrobials for the management of multidrug-resistant Gram-
negative bacteria; however, nephrotoxicity associated with these drugs is a very common …
negative bacteria; however, nephrotoxicity associated with these drugs is a very common …
Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection
GS Medeiros, MH Rigatto, DR Falci… - International journal of …, 2019 - Elsevier
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) bloodstream
infections (BSIs) are related to high mortality rates, and combination therapy has been …
infections (BSIs) are related to high mortality rates, and combination therapy has been …
[HTML][HTML] Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review
SM Nørgaard, CS Jensen, J Aalestrup… - … Resistance & Infection …, 2019 - Springer
Background Antimicrobial resistance is an increasingly serious threat to public health, and
the increased occurrence of multidrug-resistant (MDR) bacteria is a concern in both high …
the increased occurrence of multidrug-resistant (MDR) bacteria is a concern in both high …
[HTML][HTML] Polymyxins: to combine or not to combine?
Polymyxins have been a mainstay for the treatment of extensively drug resistant (XDR) Gram-
negative bacteria for the past two decades. Many questions regarding the clinical use of …
negative bacteria for the past two decades. Many questions regarding the clinical use of …
Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?
C Sarda, F Fazal, J Rello - Expert review of respiratory medicine, 2019 - Taylor & Francis
Introduction: Treatment of ventilator-associated pneumonia (VAP) is a major challenge. The
increase in multi-drug resistant bacteria has not been accompanied by the validation of new …
increase in multi-drug resistant bacteria has not been accompanied by the validation of new …